In addition, according to our recent reports that oridonin targets a downstream pathway of BCR-ABL (i.e., MYC-miR-17/20a-BIM-S) to induce apoptosis and reverse chemoresistance in leukemia cells16, 17, our current finding that oridonin targets BCR-ABL as well as MYC for degradation would better explain the efficacy of oridonin. This evidence concerns the gene ABL1 and leukemia.